Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?
Baker
Glen B
GB
Sowa
Bernard
B
Todd
Kathryn G
KG
D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors / Q000378:metabolism; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology; D020912:Moclobemide / Q000494:pharmacology / Q000627:therapeutic use; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D010624:Phenelzine / Q000494:pharmacology / Q000627:therapeutic use; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use; D014191:Tranylcypromine / Q000494:pharmacology / Q000627:therapeutic use